

COVID-19/Flu Vaccine Comparison Chart for 2026/2027												
	COVID-19 Vaccines							Influenza Vaccines				
Vaccine Formulation	Spikevax™ Moderna			Comirnaty® Pfizer			Nuvaxovid® Sanofi	Flucelvax® Seqirus	Fluviral GlaxoSmithKline	Fluzone® Sanofi		Fluad® Seqirus
Vaccine Type	mRNA			mRNA			Recombinant protein, adjuvanted	IIV3-cc	IIV3-SD	IIV3-SD		IIV3-Adj
Formats available	2.5 mL MDV 10 doses/vial	2.5 mL MDV 5 doses/vial	0.5 mL single dose PFS	0.3 mL single dose vial	2.25 mL MDV 6 doses/vial	0.3 mL single dose PFS	0.5 mL single dose PFS	0.5 mL single dose PFS	6 mL MDV (containing 5 mL of vaccine) 10 doses/vial	5.0 mL MDV 10 doses/vial	0.5 mL single dose PFS	0.5 mL single dose PFS
Authorized Age Group	6 months to less than 12 years	12 years and older		5 years to less than 12 years	12 years and older		12 years and older	6 months and older	6 months and older	6 months and older		65 years and older
Dose	0.25 mL	0.5 mL		0.3 mL	0.3 mL		0.5 mL	0.5 mL	0.5 mL	0.5 mL		0.5 mL
2-8° C Stability	60 days			10 weeks		Until expiry date	Until expiry date	Until expiry date	13 months	Until expiry date		Until expiry date
Dilution	NONE											
Routine Schedule	*1 or 2 doses **2 doses: 6m to less than 5 years of age and previously <u>not</u> vaccinated, with second dose 8 weeks after the first dose. 1 dose: 6m to less than 5 years of age and <u>previously vaccinated</u> , or ≥ 5 years of age regardless of previous vaccination			*1 dose				1 or 2 doses: 2 doses: 6m to less than 9 years of age and previously <u>not</u> vaccinated against the flu, with second dose at least 4 weeks after the first dose. 1 dose: 6m to less than 9 years of age and <u>previously vaccinated</u> against the flu, or ≥ 9 years of age regardless of previous vaccination against the flu.				1 dose
Notes	*If not previously vaccinated, individuals six months of age and older who are moderately to severely immunocompromised are eligible to receive additional doses. Refer to Table 1: COVID-19 vaccines: Canadian Immunization Guide - Canada.ca . A recommendation from a primary care provider or clinical specialist (i.e., CCMB) is required for the additional doses. **Recommended interval is 8 weeks but minimum interval is 4 weeks											
Abbreviations	IIV3-cc: standard-dose, cell culture-based, inactivated influenza vaccine, trivalent IIV3-SD: standard-dose, egg-based, inactivated influenza vaccine, trivalent IIV3-Adj: adjuvanted inactivated influenza vaccine, trivalent							mRNA: messenger ribonucleic acid MDV: multi-dose vial PFS: pre-filled syringe				